Psychotropic medication in the elderly. A survey of prescribing and clinical outcome.
Due to the increasing elderly population, an increased number of elderly patients requires treatment for mental and behavioural disorders. There are relatively few clinical studies of the prescribing of psychotropic drugs in patients over 65 years of age. A prospective study was undertaken at three centres caring for the elderly, encompassing patients from general nursing homes and a psychiatric department. Entry of patients into the survey was determined by the clinical decision to prescribe psychotropic medication and an age of 65 years or older. Included in the study were 160 patients. The main reasons for initiating psychotropic medication were indicated, and anamnestic data were collected. Initial and continuing dosages of psychotropic medication were recorded. The clinical condition was assessed at the start of treatment and after four and eight weeks, utilising the Clinical Global Impressions (CGI) scale. The patient's daily activity using an abbreviated Stockton Geriatric Rating Scale (SGRS) was assessed. Side effects were recorded using the UKU Scale. Clinical improvement was seen in about half of the patients with the best effect in patients with mainly psychotic symptoms. Patients with chronic dementia-related problems responded less well. Side effects were few and generally mild. This situation may relate to cautious introduction of the medication and adoption of low-dose regimens. All centres avoided, if possible, psychotropic polypharmacy.
Olsen
R B
RB
Geropsychiatric Department, Copenhagen County Hospital Nordvang, Glostrup.
Gydesen
S U
SU
Kristensen
M
M
Eschen
F T
FT
Sørensen
C
C
Hasle
H
H
Lund
S
S
Baastrup
P C
PC
Gylding-Sabroe
J
J
D000275:Adjustment Disorders / Q000188:drug therapy; D000368:Aged; D000369:Aged, 80 and over; D000928:Antidepressive Agents / Q000627:therapeutic use; D014150:Antipsychotic Agents / Q000627:therapeutic use; D001714:Bipolar Disorder / Q000188:drug therapy; D003704:Dementia / Q000188:drug therapy; D005260:Female; D006801:Humans; D006993:Hypnotics and Sedatives / Q000627:therapeutic use; D008297:Male; D001523:Mental Disorders / Q000188:drug therapy*; D009497:Neurotic Disorders / Q000188:drug therapy; D010259:Paranoid Disorders / Q000188:drug therapy; D011446:Prospective Studies; D011619:Psychotropic Drugs / Q000009:adverse effects / Q000627:therapeutic use*
D000928:Antidepressive Agents; D014150:Antipsychotic Agents; D006993:Hypnotics and Sedatives; D011619:Psychotropic Drugs